Ángel Manuel
Gil Agudo
Ángel Manuel Gil Agudo-rekin lankidetzan egindako argitalpenak (1)
2024
-
Randomised, double-blind, placebo-controlled, parallel-group, multicentric, phase IIA clinical trial for evaluating the safety, tolerability, and therapeutic efficacy of daily oral administration of NFX88 to treat neuropathic pain in individuals with spinal cord injury
Spinal Cord, Vol. 62, Núm. 8, pp. 454-467